Clinical trial NCT04859205: The SUPPORT-Pro Online Platform for Healthcare Professionals Treating Individuals Living With T1D
Official title: The SUPPORT-Pro Online Platform: Helping Healthcare Professionals to Increase Their Confidence Levels in Treating Individuals Living With T1D
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Educational Activities
Keywords: Type 1 diabetes
Lead sponsor: McGill University
Sponsor class: OTHER
Collaborators: name: Institut de Recherches Cliniques de Montreal
First posted: 2021-04-26
Enrollment: 229
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This study is a non-randomized pre-post trial.
Primary purpose: OTHER

Brief summary: Health care professionals (HCPs) help an support patients living with type 1 diabetes (PWT1D) who need to achieve optimal blood glucose control in order to prevent short and long term complications of T1D. However, studies show that not all HCPs are aware of T1D management as most of them only see PWT1D occasionally. This makes it difficult for HCPs to remain aware of the particularities of the condition and stay up-to-date on rapidly evolving technologies and therapies available. Moreover, low confidence levels and the inaccessibility to continuing medical education on the specificities of new therapies and technologies might increase the failure of HCPs to propose the optimal treatment plan to their PWT1D.

The SUPPORT online platform, that was first developed for PWT1D, was adjusted to suit the needs of HCPs (SUPPORT-Pro). The regularly updated bilingual (English and French) peer-reviewed content of SUPPORT, which covers the various elements that an individual with T1D needs to know to manage the disease and aims at making a better use of technologies and new therapies, is the first in its kind and is highly relevant for HCPs.

The main objective of this study is to determine if the SUPPORT-Pro online training platform can increase HCPs' (dietitians, nurses, pharmacists, medical doctors) confidence level in treating individuals with T1D. This study is a non-randomized pre-post trial. We hypothesize that the training provided through the SUPPORT-Pro online platform will significantly increase HCPs' confidence level in treating individuals with T1D after 3 months when compared to their confidence level before the intervention.


Eligibility criteria: Inclusion Criteria:

1. Certified Health Care Professional (nurse, physician (including resident in medicine), dietitian, pharmacist) who is member of a regulatory body in Canada
2. Self-reported working with at least 1 patient with type 1 diabetes in the last six months
3. Has access to the Internet
4. Use of an active email address
5. Comprehension of English or French

Exclusion Criteria:

1. Certified diabetes educators
2. Working in a T1D specialized clinic
3. Living with T1D
4. Currently living with someone with T1D (e.g. kid, partner, etc.)
5. Working in the pharmaceutical industry

Primary outcomes:
measure: To compare the level of confidence in treating individuals with type 1 diabetes measured at 3 months to the level of confidence measured at baseline.
timeFrame: 3 months
Secondary outcomes:
measure: To compare, in each specific group of HCPs (nurses, dietitians, doctors and pharmacists), the confidence levels in treating their patients with T1D after 3 months of access to the SUPPORT-Pro platform with confidence at baseline.
timeFrame: 3 months
measure: To measure the sustainability of change in all HCPs' confidence in treating patients with T1D at 12 months
timeFrame: 12 months
measure: Time spent on the platform
timeFrame: 3 months
measure: Number of posts of the discussion forum
timeFrame: 3 months
measure: Number of completed courses
timeFrame: 3 months
measure: Number of completed categories
timeFrame: 3 months
measure: Number of viewed videos
timeFrame: 3 months
measure: Satisfaction of the platform.
timeFrame: 3 months
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Institut de Recherches Cliniques de Montréal
state: Quebec
Study officials:
affiliation: McGill University
name: Anne-Sophie Brazeau, PhD
role: PRINCIPAL_INVESTIGATOR
References: